• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies.

作者信息

Stewart David J, Ramsay Tim, Navani Vishal, Liu Geoffrey, Jiang Di Maria, Batist Gerald

机构信息

David J. Stewart, MD, University of Ottawa, Division of Medical Oncology, Ottawa, ON, Canada; Tim Ramsay, PhD, Ottawa Hospital Research Institute, Ottawa, ON, Canada; Vishal Navani, MBBS, University of Calgary, Calgary, AB, Canada; Geoffrey Liu, MD and Di Maria Jiang, MD, University of Toronto, Toronto, ON, Canada; and Gerald Batist, MDCM, McGill University, Montreal, QC, Canada.

出版信息

J Clin Oncol. 2024 Mar 10;42(8):973-974. doi: 10.1200/JCO.23.02259. Epub 2024 Jan 30.

DOI:10.1200/JCO.23.02259
PMID:38290085
Abstract
摘要

相似文献

1
Progression-Free Survival Gain: A Reliable Primary End Point for Drug Registration That Can Accelerate Patient Access to Urgently Needed Therapies.无进展生存期获益：药物注册的可靠主要终点，可加速患者获得急需治疗
J Clin Oncol. 2024 Mar 10;42(8):973-974. doi: 10.1200/JCO.23.02259. Epub 2024 Jan 30.
2
Biased Evaluation in Cancer Drug Trials-How Use of Progression-Free Survival as the Primary End Point Can Mislead.癌症药物试验中的偏倚评估——将无进展生存期用作主要终点如何会产生误导。
JAMA Oncol. 2022 May 1;8(5):679-680. doi: 10.1001/jamaoncol.2021.8206.
3
Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development.无进展生存期：作为金标准的总生存期获益和加速药物研发。
Cancer J. 2009 Sep-Oct;15(5):386-94. doi: 10.1097/PPO.0b013e3181b9c5ec.
4
Progression-free survival as an end-point in solid tumours--perspectives from clinical trials and clinical practice.无进展生存期作为实体瘤的一个终点——来自临床试验和临床实践的观点
Eur J Cancer. 2014 Sep;50(13):2303-8. doi: 10.1016/j.ejca.2014.05.024. Epub 2014 Jun 25.
5
A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model.一种新的、更可靠的方法，使用无进展生存期作为总生存期获益的预测指标：渥太华 PFS 预测模型。
Crit Rev Oncol Hematol. 2020 Apr;148:102896. doi: 10.1016/j.critrevonc.2020.102896. Epub 2020 Feb 8.
6
Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression.无进展生存期与总生存期作为抗癌药物试验的主要终点：疾病进展后治疗的影响日益显著
Curr Oncol Rep. 2009 Jan;11(1):1-2. doi: 10.1007/s11912-009-0001-y.
7
Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs.无进展生存期不应作为抗癌药物注册的主要终点。
J Clin Oncol. 2023 Nov 10;41(32):4968-4972. doi: 10.1200/JCO.23.01423. Epub 2023 Sep 21.
8
Disease-free survival as an end-point in the treatment of solid tumours--perspectives from clinical trials and clinical practice.无病生存作为实体瘤治疗的终点——来自临床试验和临床实践的观点
Eur J Cancer. 2014 Sep;50(13):2298-302. doi: 10.1016/j.ejca.2014.05.016. Epub 2014 Jun 12.
9
Overall survival: a gold standard in search of a surrogate: the value of progression-free survival and time to progression as end points of drug efficacy.总生存期：寻找替代指标的金标准：无进展生存期和进展时间作为药物疗效终点的价值。
Cancer J. 2009 Sep-Oct;15(5):395-400. doi: 10.1097/PPO.0b013e3181be231d.
10
Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Diffuse Large B-Cell Lymphoma: An Individual Patient-Level Analysis of Multiple Randomized Trials (SEAL).一线弥漫性大 B 细胞淋巴瘤中无进展生存期作为总生存期替代终点的个体患者水平分析（SEAL）。
J Clin Oncol. 2018 Sep 1;36(25):2593-2602. doi: 10.1200/JCO.2018.77.9124. Epub 2018 Jul 5.

引用本文的文献

1
It is time to rethink randomized clinical trial approaches.是时候重新思考随机临床试验方法了。
Oncologist. 2024 Sep 6;29(9):e1235-e1236. doi: 10.1093/oncolo/oyae172.
2
New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices.新型抗癌药物：在解决高价问题的同时，可靠地评估“价值”。
Curr Oncol. 2024 Apr 28;31(5):2453-2480. doi: 10.3390/curroncol31050184.